Omeros Corp. Stock
Price
Target price
€8.97
€8.97
11.020%
0.89
11.020%
€31.39
03.12.25 / Frankfurt
WKN: A0NBFF / Symbol: OMER / Name: Omeros / Stock / Biotechnology & Medical Research / Small Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Omeros Corp. Stock
Omeros Corp. dominated the market today, gaining €0.89 (11.020%).
With 19 Buy predictions and not the single Sell prediction the community is currently very high on Omeros Corp..
With a target price of 31 € there is potential for a 245.79% increase which would mean more than doubling the current price of 8.97 € for Omeros Corp..
Our community identified positive and negative aspects for Omeros Corp. stock for the coming years. 3 users see the criterium "Worthwhile Investment for the next years" as a plus for the Omeros Corp. stock. On the other hand our users think that "Non-cyclic/Cyclic" could be a problem in the future.
Pros and Cons of Omeros Corp. in the next few years
Pros
?
W********* I********* f** t** n*** y****
?
G***** c******* t* c**********
?
C******** o* t** e**********
Cons
?
S********** s********
?
M***** P*******
?
B****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Omeros Corp. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Omeros Corp. | 11.020% | 10.611% | 53.248% | -18.426% | -19.596% | 361.281% | -22.981% |
| Ardelyx Inc. | 1.720% | -3.964% | 1.395% | -6.825% | -0.463% | 180.604% | -5.108% |
| Krystal Biotech | 0.320% | 0.793% | 7.744% | 6.689% | 25.230% | 150.789% | - |
| Evolus Inc | 0.000% | -4.274% | 0.901% | -54.098% | -46.667% | -18.248% | 84.697% |
Comments
Omeros (NASDAQ:OMER) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $36.00 price target on the stock.
Show more
Ratings data for OMER provided by MarketBeat
Omeros (NASDAQ:OMER) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $36.00 price target on the stock.
Show more
Ratings data for OMER provided by MarketBeat
Omeros (NASDAQ:OMER) had its "strong-buy" rating reaffirmed by analysts at WBB Securities. They now have a $45.00 price target on the stock.
Show more
Ratings data for OMER provided by MarketBeat
News
Breakout Momentum Plays You Need to Know About
Momentum investors rely on a combination of astute analysis and timing to maximize gains. While this approach can carry a fair degree of risk, the allure of identifying a fast-growing stock and
A Deal With Novo Nordisk Sent This Stock 181% Higher Overnight. Is It a Buy Now?
Shares of Omeros (NASDAQ: OMER) finished Oct. 14's trading session at $4.10 per share. When the market opened on Oct. 15, the stock was up by 181% at $11.52 per share.
It was a deal with the Danish
Omeros Posts 2,652 Percent Sales Jump
Omeros (NASDAQ:OMER), a biopharmaceutical company focused on developing treatments for rare diseases and immune-related conditions, released its second quarter results on August 14, 2025. The